caa a22 4500 445336528 CHVBK 20180317142757.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1245/s10434-011-1761-9 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1761-9 Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases [Elektronische Daten] [Nuh Rahbari, Christoph Reissfelder, Monika Mühlbayer, Kathrin Weidmann, Christoph Kahlert, Markus Büchler, Jürgen Weitz, Moritz Koch] Background: Circulating angiogenic factors (CAF) have been shown as therapeutic targets and prognostic biomarkers in metastatic colorectal cancer. However, their correlation with circulating tumor cells (CTC) is unknown, as is their role as prognostic biomarkers in patients amenable for curative resection. Methods: Preoperative blood samples were collected in patients undergoing potentially curative resection of colorectal liver metastases. Serum levels of eight CAF and CTC were analyzed by using ELISA and CK20 RT-PCR, respectively. Prognostic factors were identified by a Cox proportional hazards model. Results: A total of 107 patients were eligible for final analyses. Circulating levels of PlGF, EGF, and bFGF were increased, whereas PDGF-A and Ang-1 levels were decreased in patients compared with healthy control subjects. CTC were detected in 36 of 63 patients (57%) and were associated with significantly lower levels of EGF and bFGF. On univariate analyses, multiple metastases (p=0.04), a MSKCC risk score >2 (p=0.004), and detection of CTC (p=0.05) were associated with disease recurrence. Multivariate analysis, including the panel of eight CAF, revealed a MSKCC score >2 [hazard ratio (HR), 2.01; 95% confidence interval (CI), 1.11-3.82; p=0.02] and low levels of circulating PlGF (HR, 0.26; 95% CI, 0.08-0.81; p=0.02) as independent predictors of poor recurrence-free survival. Conclusions: CAF may indicate patients who are at high risk for disease recurrence. The notion that CAF may identify patients who benefit from adjuvant therapy or antiangiogenic agents warrants further investigation. Society of Surgical Oncology, 2011 Rahbari Nuh Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Reissfelder Christoph Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Mühlbayer Monika Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Weidmann Kathrin Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Kahlert Christoph Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Büchler Markus Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Weitz Jürgen Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Koch Moritz Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2182-2191 1068-9265 18:8<2182 2011 18 10434 https://doi.org/10.1245/s10434-011-1761-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1761-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rahbari Nuh Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Reissfelder Christoph Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Mühlbayer Monika Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Weidmann Kathrin Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Kahlert Christoph Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Büchler Markus Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Weitz Jürgen Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Koch Moritz Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2182-2191 1068-9265 18:8<2182 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer